GlassScriptPhysician profile
Matthew J Reschly
NPI 1417949777
$10,247.01
in general payments reported to CMS, 2019-2025
32 companies · $2,416 in 2025
The $2,416 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,090 · 2020: $260 · 2021: $548 · 2022: $2,046 · 2023: $1,756 · 2024: $2,131 · 2025: $2,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,203 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,202.89 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,416.04 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $852.79 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $850.75 | 2019-2025 | |
| Ucb, INC. | $809.77 | 2019-2025 | Bimzelx, Cimzia |
| Revance Therapeutics, INC. | $665.87 | 2024-2025 | Daxxify |
| E.R. Squibb & Sons, L.L.C. | $569.25 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $557.94 | 2019-2025 | Tremfya |
| Genzyme Corporation | $507.27 | 2019-2025 | |
| Lilly USA, LLC | $491.16 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $336.35 | 2019-2025 | Nemluvio |
| Pfizer INC. | $297.09 | 2019-2025 | |
| Leo Pharma INC. | $287.52 | 2021-2025 | Adbry, Spevigo |
| Amgen INC. | $281.57 | 2020-2023 | Otezla |
| Sun Pharmaceutical Industries INC. | $239.03 | 2019-2025 | Ilumya |
| Incyte Corporation | $191.85 | 2022-2025 | Opzelura |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $157.64 | 2019-2023 | Jublia |
| Arcutis Biotherapeutics, INC. | $148.66 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $129.13 | 2023-2024 | Vtama |
| Organon LLC | $77.59 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $73.50 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.42 | 2022-2025 | Spevigo |
| Almirall LLC | $55.90 | 2019-2025 | Seysara |
| Sanofi-Aventis U.S. LLC | $32.12 | 2021 | |
| Vyne Pharmaceuticals INC. | $24.87 | 2020 | |
| Epi Health, LLC | $24.61 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $19.96 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.61 | 2022 | |
| Celgene Corporation | $17.53 | 2019 | |
| Hydrofera LLC | $17.11 | 2022 | |
| Krystal Biotech INC | $13.68 | 2023 | Vyjuvek |
| Melinta Therapeutics, LLC | $12.84 | 2019 | |
| Mission Pharmacal Company | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Reschly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.